CJC-1295 (DAC)
What to know about CJC-1295 (DAC)
CJC-1295 DAC is a long-acting GHRH analogue designed to bind circulating albumin and extend exposure well beyond native GHRH.
- How it may work
- GHRH-receptor activation stimulates pituitary growth-hormone release; the drug-affinity-complex group binds albumin and extends the signal while retaining pulsatility.
- What research found
- Small ascending-dose studies in healthy adults reported a 5.8-8.1-day half-life, growth-hormone elevation for at least six days, and IGF-1 elevation for roughly nine to eleven days.
- What is not settled
- The early studies were small and short. They cannot define rare events or long-term endocrine, glucose, fluid-balance, cardiac, or immune risks.
- Research and product status
- CJC-1295 DAC has no licensed U.S. product and did not progress to a large outcome evidence base.
Research reference
- Research amount range
- 2–4 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Reported timing context
- The DAC form is long-acting, so it's dosed only once or twice a week rather than daily.
- What people report
- Builds over weeks as levels reach steady state.
- Model accumulation timescale
- ~35.0 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- 8–12 weeks
- Reported break context
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- A small human study found growth hormone remained elevated for at least six days and IGF-1 for roughly nine to eleven days after one administration. These are biomarkers, not visible or functional outcomes.
- When to assess
- The study supports a prolonged hormone signal but does not define when to expect changes in sleep, recovery, muscle, or body composition. It supplies no validated multiweek success checkpoint.
- Conditions and limitations
- The human study did not establish fasting, bedtime timing, or pairing with ipamorelin as necessary for an outcome. Long persistence also means frequent administration cannot be inferred from short-acting analogues.
- When to stop
- No validated target, course length, maintenance phase, or quit rule exists for common research use. Absent subjective change does not justify stacking or shortening the interval.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about CJC-1295 (DAC) alongside other compounds or medicines.
Key properties
- Formula
- C165H269N47O46
- Mol. weight
- 3,647.2 Da
- CAS
- 863288-34-0
- PubChem CID
- 91971820
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Vial arithmetic
Published research contexts for CJC-1295 (DAC) describe 2–4 mg per administration. Descriptive only, not a recommendation.
About 6–8 days; the albumin-binding DAC is what stretches it to that range.
Research schedule reference
Reported schedule context for CJC-1295 (DAC); not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported rangeThe DAC form is long-acting, so it raises a sustained rise rather than a sharp pulse. Weekly spacing follows the multi-day half-life. | ~30–60 mcg/kg (about 2–4 mg for a 70 kg adult) | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.98× single dose
- Time to steady state
- 35.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Teichman SL et al., JCEM 2006;91:799Single and multiple ascending doses of CJC-1295 with DAC; 30 and 60 mcg/kg were well tolerated with a half-life of ~5.8–8.1 days.